Literature DB >> 16511755

A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms.

Jesus Rodriguez-Baño, David L Paterson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16511755     DOI： 10.1086/500945

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  17 in total

1.  Detection of CTX-M-type extended-spectrum beta-lactamase (ESBLs) by testing with MicroScan overnight and ESBL confirmation panels.

Authors:  James H Jorgensen; M L McElmeel; L C Fulcher; B L Zimmer
Journal:  J Clin Microbiol       Date:  2009-11-04       Impact factor: 5.948

2.  Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.

Authors:  M Arnan; C Gudiol; L Calatayud; J Liñares; M Á Dominguez; M Batlle; J M Ribera; J Carratalà; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-30       Impact factor: 3.267

3.  Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.

Authors:  Jennifer H Han; Kei Kasahara; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

4.  Features of infections due to Klebsiella pneumoniae carbapenemase-producing Escherichia coli: emergence of sequence type 131.

Authors:  Young Ah Kim; Zubair A Qureshi; Jennifer M Adams-Haduch; Yoon Soo Park; Kathleen A Shutt; Yohei Doi
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

5.  First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.

Authors:  James S Lewis; Monica Herrera; Brian Wickes; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

6.  Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.

Authors:  Mario Tumbarello; Michela Sali; Enrico Maria Trecarichi; Fiammetta Leone; Marianna Rossi; Barbara Fiori; Gennaro De Pascale; Tiziana D'Inzeo; Maurizio Sanguinetti; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

7.  The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities.

Authors:  Sophie Vimont; Anders Boyd; Alexandre Bleibtreu; Marcelle Bens; Jean-Michel Goujon; Louis Garry; Olivier Clermont; Erick Denamur; Guillaume Arlet; Alain Vandewalle
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

8.  Change of antimicrobial susceptibility among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis.

Authors:  Seung-Kwan Lim; In Whee Park; Wee Gyo Lee; Hyun Kyung Kim; Young Hwa Choi
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

9.  Increasing resistance in commensal Escherichia coli, Bolivia and Peru.

Authors:  Alessandro Bartoloni; Lucia Pallecchi; Costanza Fiorelli; Tiziana Di Maggio; Connie Fernandez; Ana Liz Villagran; Antonia Mantella; Filippo Bartalesi; Marianne Strohmeyer; Angela Bechini; Herlan Gamboa; Hugo Rodriguez; Charlotte Kristiansson; Göran Kronvall; Eduardo Gotuzzo; Franco Paradisi; Gian Maria Rossolini
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

10.  Comparison of Second- and Third-Generation Cephalosporin as Initial Therapy for Women with Community-Onset Uncomplicated Acute Pyelonephritis.

Authors:  U-Im Chang; Hyung Wook Kim; Seong-Heon Wie
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.